#157678

RMA.Trh4 Kb KO cells

Cat. #157678

RMA.Trh4 Kb KO cells

Cat. #: 157678

Sub-type: Primary

Unit size: 1x10^6 cells / vial

Availability: 3-4 weeks

Organism: Mouse

Tissue: Lymphatic Tissue

Disease: Cancer

Model: Knock-Out

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Thorbald Van Hall

Institute: Leiden University and Leiden University Medical Center; Stichting Oncode Institute

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: RMA.Trh4 Kb KO cells
  • Tool sub type: Primary
  • Parental cell: RMA
  • Organism: Mouse
  • Tissue: Lymphatic Tissue
  • Disease: Cancer
  • Model: Knock-Out
  • Description: This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Kb gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo-antigen selectively presented by cells with processing defects in the classical MHC class I (MHC-I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide t...
  • Production details: Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/Cas9 technology
  • Biosafety level: 1
  • Additional notes: CRISPR edited RMA cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide...
  • Recommended controls: RMA.Trh4 Db KO cells
  • Cellosaurus id: CVCL_J385

Target Details

  • Target: Trh4 Kb KO

Applications

  • Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

  • Format: Frozen
  • Growth medium: Suspension cells in DMEM+8% FCS
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

References

  • Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.